<DOC>
	<DOCNO>NCT01171989</DOCNO>
	<brief_summary>The current trial evaluate safety immunogenicity GSK Biologicals ' GSK2202083A vaccine administer booster dose follow prim first year life vaccine . This protocol post deal objective &amp; outcome measure booster phase . The objective &amp; outcome measure primary phase present separate protocol posting ( NCT number = NCT00970307 ) .</brief_summary>
	<brief_title>Immunogenicity Safety Study GlaxoSmithKline Biologicals ' GSK2202083A Vaccine Administered Booster Dose</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Poliomyelitis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe parent ( ) / legally acceptable representative ( ) comply requirement protocol . Subjects complete full threedose primary vaccination course accord group allocation primary study DTPaHBVIPV=HibMenCTT002 ( 112157 ) . A male female , include , 12 18 month age time booster vaccination . Written inform consent obtain parent ( ) / legally acceptable representative ( ) subject . Healthy subject establish medical history clinical examination enter study . Child care . Use investigational nonregistered product study vaccine within 30 day precede dose study vaccine , plan use study period . Chronic administration immunosuppressant immunemodifying drug within six month prior booster vaccination . Planned administration/administration immunoglobulin and/or blood product within three month booster dose , study period . Planned administration/administration vaccine foreseen study protocol period start 30 day end 30 day booster dose . Participation another clinical study since primary study DTPaHBVIPV/HibMenCTT002 subject expose investigational noninvestigational product . Evidence previous diphtheria , tetanus , pertussis , hepatitis B , poliomyelitis , Hib , pneumococcal MenC vaccination disease since conclusion visit study DTPaHBVIPV/HibMenCTT002 . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . History reaction hypersensitivity likely exacerbate component vaccine . The following adverse event occur previous administration DTP vaccine : Encephalopathy . Temperature &gt; = 40.5°C ( rectal temperature ) within 48 hour vaccination , due another identifiable cause . Collapse shocklike state within 48 hour vaccination . Persistent , inconsolable cry occur within 48 hour vaccination last &gt; = 3 hour . Seizures without fever occur within 3 day vaccination . The following condition temporary selflimiting , subject may vaccinate condition resolve exclusion criterion meet : • Acute disease and/or fever time enrolment . Fever define temperature ≥ 37.5°C oral , axillary tympanic setting , ≥ 38.0°C rectal setting . Subjects minor illness without fever may enrol discretion investigator .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>18 Months</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>booster vaccination</keyword>
	<keyword>combine vaccine</keyword>
</DOC>